ViCentra raises $85M, preps for US entry

UTRECHT, the Netherlands — ViCentra, a European medical device company redefining insulin delivery for people with diabetes, has announced the successful close of an upsized $85 million Series D financing led by new investor Innovation Industries, with matching participation from existing investors Partners in Equity and Invest-NL and continued support from EQT Life Sciences and Health Innovations. With this fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry. Kaleido is an insulin patch pump that is discreet, intuitive and personalized. “ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience – combining clinical performance with design simplicity and wearability,” said Caaj Greebe, partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.” ViCentra says the global insulin delivery market is one of the largest and fastest growing medical device segments, driven by the rising prevalence of diabetes and increasing demand for solutions that blend clinical effectiveness with everyday usability. The insulin pump market, alone, is projected to reach over $14 billion by 2034. The company says patch pumps represent the fastest-growing segment of the insulin delivery market, signaling a broader industry shift toward compact, wearable and patient-centric solutions.